Free tool
FAERS Monitor: Opvee
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217470 or its brand name (Opvee, Nalmefene Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
43
Serious
35
81% of reports
Hospitalization
16
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- coma5
- therapy non-responder5
- bradycardia4
- bradypnoea4
- electrocardiogram qt prolonged4
- hypothermia4
- intentional overdose4
- miosis4
- pneumonia aspiration4
- diabetic ketoacidosis3
- drug withdrawal syndrome3
- nausea3
- off label use3
- pulmonary oedema3
- sudden death3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2010 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 7 |
| 2025 | 11 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bradypnoeaSignal | 4 | 726.2 | 285.4 | 2,214 |
| miosisSignal | 4 | 243.9 | 95.9 | 740 |
| hypothermiaSignal | 4 | 193.3 | 76.0 | 585 |
| sudden deathSignal | 3 | 138.7 | 46.6 | 284 |
| pneumonia aspirationSignal | 4 | 78.3 | 30.8 | 233 |
| diabetic ketoacidosisSignal | 3 | 61.1 | 20.5 | 122 |
| therapy non-responderSignal | 5 | 54.4 | 23.9 | 212 |
| electrocardiogram qt prolongedSignal | 4 | 54.4 | 21.4 | 160 |
| comaSignal | 5 | 51.4 | 22.5 | 200 |
| bradycardiaSignal | 4 | 36.9 | 14.5 | 106 |
| pulmonary oedemaSignal | 3 | 32.8 | 11.0 | 64 |
| intentional overdoseSignal | 4 | 30.5 | 12.0 | 87 |
| drug withdrawal syndromeSignal | 3 | 16.7 | 5.6 | 30 |
| nausea | 3 | 1.9 | 0.6 | 0 |
| off label use | 3 | 1.7 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.